Desai Shrinivas B, Patil Abhijit A, Nikam Rahul, Desai Ajinkya S, Bachhav Vrushali
Department of Imaging and Interventional Radiology, Jaslok Hospital and Research Center, Mumbai, Maharashtra, India.
J Clin Imaging Sci. 2012;2:74. doi: 10.4103/2156-7514.104307. Epub 2012 Dec 4.
To study the results of magnetic resonance-guided focused ultrasound surgery (MRgFUS) treatment carried out on Indian patients in our Hospital.
Fifty Indian women (mean age = 36.2 ± 8.3 years) were treated for fibroids as outpatients using the ExAblate MRgFUS system (InSightec). Non-perfused volumes (NPVs) were measured immediately after treatment to calculate the treatment outcomes. A validated symptom-specific questionnaire to record their symptoms prior to treatment and six months following treatment was completed by patients. The size of the fibroids was measured on the day of the treatment and during the 6-month checkup to calculate shrinkage. Adverse events during and following treatment were recorded and monitored.
The average NPV ratio measured after the treatment was 88% ± 6%, indicative of high ablated fibroid tissue. Prior to treatment, the mean Symptoms Severity Score was 56.9 ± 4.8 (n = 50), which is indicative of highly symptomatic patients. Six months following treatment, there was an average fibroid shrinkage of 30% ± 11%, and a significant decrease in the mean score to 28.6 ± 6.0 (n = 50) (P < 0.001). There were no reports of serious or unexpected adverse events at any point during treatment or during the follow-up period from any of the 50 women treated in the current study.
The current results obtained after 6 months of treatment corroborated previous data on the safety and efficacy of MRgFUS for treating uterine fibroids. This is the first publication that provides such data for a large cohort of Indian women.
研究我院对印度患者进行磁共振引导聚焦超声手术(MRgFUS)治疗的结果。
50名印度女性(平均年龄=36.2±8.3岁)作为门诊患者使用ExAblate MRgFUS系统(InSightec)治疗子宫肌瘤。治疗后立即测量非灌注体积(NPV)以计算治疗效果。患者完成一份经过验证的特定症状问卷,记录治疗前和治疗后6个月的症状。在治疗当天和6个月检查时测量肌瘤大小以计算缩小情况。记录并监测治疗期间及之后的不良事件。
治疗后测得的平均NPV比率为88%±6%,表明肌瘤组织消融程度高。治疗前,平均症状严重程度评分为56.9±4.8(n=50),表明患者症状严重。治疗6个月后,肌瘤平均缩小30%±11%,平均评分显著降至28.6±6.0(n=50)(P<0.001)。在本研究中接受治疗的50名女性中,在治疗期间或随访期间的任何时间均未报告严重或意外不良事件。
治疗6个月后获得的当前结果证实了先前关于MRgFUS治疗子宫肌瘤的安全性和有效性的数据。这是首次为大量印度女性群体提供此类数据的出版物。